Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.48 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.48 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL19100769 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Trimethylammonium SCHEMBL19100741 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL432885 | 0.94 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL2305805 | 0.94 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL398655 | 0.94 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL1056613 | 0.94 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100895 | 0.93 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100618 | 0.93 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100890 | 0.93 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL19100949 | 0.91 | ALDH1A1 (0.51) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218739-A2 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | The Regents of The University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2022115488-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220160644-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-26 | — | — | US | claimed |
| US-20200383929-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-10 | — | — | US | claimed |
| US-10765636-B2 | Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | claimed |
| US-20190160015-A1 | MESOPOROUS SILICA NANOPARTICLES WITH A LIPID BILAYER COATING FOR CARGO DELIVERY | UNIV CALIFORNIA (US) | 2019-05-30 | — | — | US | claimed |
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2024-01-11 | — | — | US | disclosed |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023172300-A1 | A DRUG NANOCARRIER SYSTEM TO DELIVER A COMBINATION OF TLR AGONISTS AND/OR A LIPOXIN PLUS IMMUNOGENIC CELL DEATH INDUCING CHEMOTHERAPEUTIC AGENTS FOR CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230241000-A1 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4218739-A2 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | The Regents of The University of California (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4192465-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20190216736-A1 | SCALE UP SYNTHESIS OF SILICASOME NANOCARRIERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| US-20190160015-A1 | MESOPOROUS SILICA NANOPARTICLES WITH A LIPID BILAYER COATING FOR CARGO DELIVERY | UNIV CALIFORNIA (US) | 2019-05-30 | — | — | US | disclosed |
| US-10143660-B2 | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018213631-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-3399966-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | The Regents of the University of California (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180098945-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-12 | — | — | US | disclosed |
| WO-2017120537-A1 | MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241244-A1 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | IDO1, IDO2, BID | ALDH1A1 1131/4885TSHR 4718/4885LMNA 2187/4885 |
| US-20240009321-A1 | IMMUNOGENIC NANOVESICLES FOR CANCER IMMUNOTHERAPY | SGMS1, SGMS2, SMPD3 | ALDH1A1 3243/4885TSHR 4195/4885LMNA 1555/4885 |
| US-20230338363-A1 | COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1 | SQSTM1, PDCD1, CD274 | ALDH1A1 2695/4885TSHR 4524/4885LMNA 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.